{"id":"NCT04753697","sponsor":"Celgene","briefTitle":"A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis","officialTitle":"A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-22","primaryCompletion":"2024-01-11","completion":"2024-08-29","firstPosted":"2021-02-15","resultsPosted":"2025-03-13","lastUpdate":"2025-03-13"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis"],"interventions":[{"type":"DRUG","name":"CC-93538","otherNames":["RPC4046"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Administration of CC-93538","type":"EXPERIMENTAL"},{"label":"Administration of CC-93538 and Placebo","type":"EXPERIMENTAL"},{"label":"Administration of Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase.\n\nParticipants will be randomized at the beginning of the study into 3 treatment arms:\n\n* Placebo for Induction and Maintenance\n* CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance\n* CC-93538 360 mg SC once weekly for Induction and Maintenance","primaryOutcome":{"measure":"Change From Baseline in Mean Dysphagia Days (DD) at Week 24","timeFrame":"Baseline (Day 1) and Week 24","effectByArm":[{"arm":"Induction Phase - CC-93538 360 mg QW","deltaMin":-6.85,"sd":5.259},{"arm":"Induction Phase - Placebo","deltaMin":-4.98,"sd":5.075}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":212,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Germany","Israel","Italy","Japan","Poland","Portugal","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["39384067"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsclinicaltrials.com/us/en/home"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":167},"commonTop":["COVID-19","Injection site reaction","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}